New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy
N6-methylation is a modification in which a methyl group is added to the adenine base of a nucleotide. This modification is crucial for controlling important functions that are vital for gene expression, including mRNA splicing, stability, and translation. Due to its intricate participation in both...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1533940/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591700812365824 |
|---|---|
| author | Mengran Li Mengran Li Hu Tian Yanshuang Zhuang Zili Zhang Zili Zhang |
| author_facet | Mengran Li Mengran Li Hu Tian Yanshuang Zhuang Zili Zhang Zili Zhang |
| author_sort | Mengran Li |
| collection | DOAJ |
| description | N6-methylation is a modification in which a methyl group is added to the adenine base of a nucleotide. This modification is crucial for controlling important functions that are vital for gene expression, including mRNA splicing, stability, and translation. Due to its intricate participation in both normal cellular processes and the course of disease, as well as its critical role in determining cell fate, N6-methyladenosine (m6A) alteration has recently attracted a lot of interest. The formation and progression of many diseases, especially cancer, can be attributed to dysregulated m6A alteration, which can cause disturbances in a variety of cellular functions, such as immunological responses, cell proliferation, and differentiation. In this study, we examine how m6A dysregulation affects hepatocellular carcinoma (HCC), with a particular emphasis on how it contributes to immunological evasion and carcinogenesis. We also investigate its potential as a novel therapeutic target, providing new perspectives on potential therapeutic approaches meant to enhance clinical results for patients with HCC. |
| format | Article |
| id | doaj-art-5e654bb9a2c140efa5d5754c430fe667 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-5e654bb9a2c140efa5d5754c430fe6672025-01-22T07:11:14ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.15339401533940New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapyMengran Li0Mengran Li1Hu Tian2Yanshuang Zhuang3Zili Zhang4Zili Zhang5Department of Science and Technology, Taizhou Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Taizhou, Jiangsu, ChinaSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Science and Technology, Taizhou Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Taizhou, Jiangsu, ChinaDepartment of Science and Technology, Taizhou Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Taizhou, Jiangsu, ChinaDepartment of Science and Technology, Taizhou Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Taizhou, Jiangsu, ChinaSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, ChinaN6-methylation is a modification in which a methyl group is added to the adenine base of a nucleotide. This modification is crucial for controlling important functions that are vital for gene expression, including mRNA splicing, stability, and translation. Due to its intricate participation in both normal cellular processes and the course of disease, as well as its critical role in determining cell fate, N6-methyladenosine (m6A) alteration has recently attracted a lot of interest. The formation and progression of many diseases, especially cancer, can be attributed to dysregulated m6A alteration, which can cause disturbances in a variety of cellular functions, such as immunological responses, cell proliferation, and differentiation. In this study, we examine how m6A dysregulation affects hepatocellular carcinoma (HCC), with a particular emphasis on how it contributes to immunological evasion and carcinogenesis. We also investigate its potential as a novel therapeutic target, providing new perspectives on potential therapeutic approaches meant to enhance clinical results for patients with HCC.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1533940/fullhepatocellular carcinomaRNA N6-methyladenosine modificationimmunotherapytherapeutic targetclinical treatment |
| spellingShingle | Mengran Li Mengran Li Hu Tian Yanshuang Zhuang Zili Zhang Zili Zhang New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy Frontiers in Immunology hepatocellular carcinoma RNA N6-methyladenosine modification immunotherapy therapeutic target clinical treatment |
| title | New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy |
| title_full | New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy |
| title_fullStr | New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy |
| title_full_unstemmed | New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy |
| title_short | New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy |
| title_sort | new insights into n6 methyladenosine in hepatocellular carcinoma immunotherapy |
| topic | hepatocellular carcinoma RNA N6-methyladenosine modification immunotherapy therapeutic target clinical treatment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1533940/full |
| work_keys_str_mv | AT mengranli newinsightsinton6methyladenosineinhepatocellularcarcinomaimmunotherapy AT mengranli newinsightsinton6methyladenosineinhepatocellularcarcinomaimmunotherapy AT hutian newinsightsinton6methyladenosineinhepatocellularcarcinomaimmunotherapy AT yanshuangzhuang newinsightsinton6methyladenosineinhepatocellularcarcinomaimmunotherapy AT zilizhang newinsightsinton6methyladenosineinhepatocellularcarcinomaimmunotherapy AT zilizhang newinsightsinton6methyladenosineinhepatocellularcarcinomaimmunotherapy |